Commandité

Bharat Bio successfully completes Phase III trials of new oral cholera vaccine Hillchol

Bharat Biotech's oral cholera vaccine, Hillchol, has demonstrated successful Phase III clinical trial results, proving effective against both Ogawa and Inaba serotypes. The vaccine exhibited a significant rise in vibriocidal antibodies and maintained a strong safety profile across all age groups. With production capacity of 200 million doses, Hillchol can address the global cholera crisis and vaccine shortages.
Rechercher
Catégories
Lire la suite
Economic Digest: Nepal’s Business News in a Nutshell
KATHMANDU: Economic Digest offers a concise yet comprehensive overview of significant business...
Par HamroGlobal 0 6
'He’s winning it' – Rishabh Pant drops Wimbledon 2025 prediction – Watch
Rishabh Pant, the dynamic Indian wicketkeeper-batter, made his Wimbledon debut amidst a break...
Par BharatUpdates 0 23
One killed, another injured in lightning strike in Taplejung
TAPLEJUNG: A man has died and another has been injured after being struck by lightning in...
Par HamroGlobal 0 33
Neena Gupta opens up about her FIRST husband
Neena Gupta reminisced about her early romances. Her first love was an IIT student, whom she...
Par BharatUpdates 0 36
RCB stampede chargesheet only after HC nod
Par BharatUpdates 0 42